GrandPharm obtained the right to commercialize BRM421,a new drug for dry eye syndrome, in mainland China, HK and Macau.
GrandPharm obtained the right to develop and commercialize BRM421 in greater China. At the same time, GrandPharm subscribed for a small amount of equity of Brimbiotech
|Global M&A Offices||
Hollyhigh International Capital (Global M&A China)
|Global M&A Advisory||Advisor to the seller|
For further details, see: https://www.brimbiotech.com/en...